Find trials
Consejos para buscar

Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke

Overview

Información sobre este estudio

This is a randomized, placebo-controlled, phase 3 clinical trial to evaluate the efficacy and safety of transcranial ultrasound (US) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  1. Males or females 18 - 80 years of age
  2. Subjects presenting within timeframe for intravenous tPA treatment approved by local regulatory authorities but no more than 0-3 hours from onset of symptoms
  3. No signs of intracranial bleeding on assessment by non-contrast CT or non-contrast MRI
  4. Subjects with neurological deficits of a total NIHSS score ≥ 10 points
  5. Subjects that in the opinion of the treating physician require treatment with full dose IV tPA as standard of care per institutional standards
  6. SBP ≤ 185 mmHg and DBP ≤ 105 mmHg at baseline or after treatment of hypertension with medications prior to tPA bolus
  7. Pre-morbid modified Rankin score of 0-1
  8. Provision of informed consent as demonstrated by the subject's signature or by the signature of the subject's authorized legal representative on the Informed Consent Form in accordance with all local and national regulations
  9. Co-signature on the Informed Consent Form by a qualified member of the study staff signifying that, in his/her professional opinion, informed consent has been obtained in accordance with all local and national regulations
  10. For subjects in the optional arterial recanalization substudy:
    1. Occlusion located in the intracranial carotid tee through mid M2 or proximal A2, or intracranial vertebrobasilar or P1/proximal P2 segments or tandem lesions
    2. Measured glomerular filtration rate (GFR) ≥ 60 mL/min for patients undergoing CTA or MRA

Exclusion Criteria:

  1. Subjects with primary intra-arterial thrombolysis
  2. Females who are pregnant or breast feeding
  3. Subjects receiving other investigational drugs, procedures, or therapies within 30 days prior to study treatment
  4. Subjects with any standard contraindication for intravenous tPA therapy
  5. Significant concurrent medical/neurological conditions or test values that, in the opinion of the investigator, pose significant risk to the subject and warrant exclusion from the study
  6. Participation in this study may exclude you from participating in other clinical trials

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Cumara O'Carroll, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20119089

Mayo Clinic Footer